CANABIDIOL NO MANEJO DA DOR ASSOCIADA À DISFUNÇÃO TEMPOROMANDIBULAR
DOI:
https://doi.org/10.56238/levv17n58-080Palavras-chave:
Canabidiol, Disfunção Temporomandibular, Dor Orofacial, Dor Miofascial, Sistema EndocanabinoideResumo
A disfunção temporomandibular (DTM) constitui um conjunto de condições que afetam a articulação temporomandibular e estruturas associadas, sendo uma das principais causas de dor orofacial não odontogênica. Diante das limitações das abordagens terapêuticas convencionais, o canabidiol (CBD) tem emergido como uma alternativa potencial no manejo da dor, devido às suas propriedades analgésicas, anti-inflamatórias e moduladoras do sistema endocanabinoide. O presente estudo teve como objetivo analisar criticamente as evidências científicas acerca do uso do canabidiol no manejo da dor associada à DTM. Trata-se de uma revisão narrativa de literatura, com abordagem qualitativa, realizada nas bases de dados PubMed, SciELO e ScienceDirect, contemplando publicações no período de 2015 a 2025. Foram incluídos estudos clínicos, revisões e pesquisas experimentais que abordassem direta ou indiretamente a utilização do CBD em dor orofacial, dor miofascial ou DTM. Os resultados evidenciaram uma predominância de estudos indiretos, incluindo revisões e modelos experimentais, com número limitado de ensaios clínicos randomizados. Destacam-se dois estudos clínicos recentes que demonstraram redução significativa da dor e da atividade muscular em pacientes com DTM tratados com canabidiol. Adicionalmente, evidências pré-clínicas indicam efeitos analgésicos e anti-inflamatórios do CBD, reforçando sua plausibilidade biológica. No entanto, a heterogeneidade metodológica dos estudos e a escassez de evidências clínicas robustas limitam a generalização dos achados. Conclui-se que o canabidiol apresenta potencial terapêutico no manejo da dor associada à DTM, especialmente de origem muscular, sendo necessários estudos clínicos adicionais para estabelecer sua eficácia, segurança e aplicabilidade clínica.
Downloads
Referências
BARON, E. P. et al. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. The Journal of Headache and Pain, v. 19, n. 1, p. 37, 2018. DOI: https://doi.org/10.1186/s10194-018-0862-2.
BOYCHUK, D. G. et al. The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review. Journal of Oral & Facial Pain and Headache, v. 29, n. 1, p. 7–14, 2015. DOI: https://doi.org/10.11607/ofph.1274.
BRUNI, N. et al. Cannabinoid delivery systems for pain and inflammation treatment. Molecules, v. 23, n. 10, p. 2478, 2018. DOI: https://doi.org/10.3390/molecules23102478.
BURSTEIN, S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorganic & Medicinal Chemistry, v. 23, n. 7, p. 1377–1385, 2015. DOI: https://doi.org/10.1016/j.bmc.2015.01.059.
DAVID, C. et al. Cannabidiol in dentistry: a scoping review. Dentistry Journal, v. 10, n. 10, p. 193, 2022. DOI: https://doi.org/10.3390/dj10100193.
GOLANSKA, P. et al. Temporomandibular myofascial pain syndrome—Aetiology and biopsychosocial modulation: a narrative review. International Journal of Environmental Research and Public Health, v. 18, n. 15, p. 7807, 2021. DOI: https://doi.org/10.3390/ijerph18157807.
GROSSMAN, S.; TAN, H.; GADIWALLA, Y. Cannabis and orofacial pain: a systematic review. British Journal of Oral and Maxillofacial Surgery, v. 60, n. 6, p. e677–e690, 2021. DOI: https://doi.org/10.1016/j.bjoms.2021.03.004.
MARTINEZ NAYA, N. et al. Molecular and cellular mechanisms of action of cannabidiol. Molecules, v. 28, n. 16, p. 5980, 2023. DOI: https://doi.org/10.3390/molecules28165980.
MENA, M. et al. Efficacy of topical interventions for temporomandibular disorders compared to placebo or control therapy: a systematic review with meta-analysis. Journal of Dental Anesthesia and Pain Medicine, v. 20, n. 6, p. 337–356, 2020. DOI: https://doi.org/10.17245/jdapm.2020.20.6.337.
MLOST, J. et al. Cannabidiol for pain treatment: focus on pharmacology and mechanism of action. International Journal of Molecular Sciences, v. 21, n. 22, p. 8870, 2020. DOI: https://doi.org/10.3390/ijms21228870.
NITECKA-BUCHTA, A. et al. Myorelaxant effect of transdermal cannabidiol application in patients with temporomandibular disorders: a randomized, double-blind trial. Journal of Clinical Medicine, v. 8, n. 11, p. 1886, 2019. DOI: https://doi.org/10.3390/jcm8111886.
PISANTI, S. et al. Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacology & Therapeutics, v. 175, p. 133–150, 2017. DOI: https://doi.org/10.1016/j.pharmthera.2017.02.041.
QIAO, Y. et al. Chemokine regulation in temporomandibular joint disease: a comprehensive review. Genes, v. 14, n. 2, p. 408, 2023. DOI: https://doi.org/10.3390/genes14020408.
SERMET, S. et al. Cannabidiol selectively modulates interleukin (IL)-1β and IL-6 production in human peripheral blood monocytes. Toxicology, v. 464, p. 153016, 2021. DOI: https://doi.org/10.1016/j.tox.2021.153016.
VIVANCO-ESTELA, A. N. et al. Cannabidiol has therapeutic potential for myofascial pain in parkinsonian rats. Neuropharmacology, v. 196, p. 108700, 2021. DOI: https://doi.org/10.1016/j.neuropharm.2021.108700.
WALCZYŃSKA-DRAGOŃ, K. et al. Cannabidiol intervention for muscular tension, pain, and sleep bruxism intensity: a randomized, double-blind clinical trial. Journal of Clinical Medicine, v. 13, n. 5, p. 1417, 2024. DOI: https://doi.org/10.3390/jcm13051417.
WEERATHATAPHAN, S. et al. Cannabinoids and orofacial pain management: a review. International Journal of Dentistry and Oral Science, v. 8, p. 5123–5132, 2021.
WONG, H.; CAIRNS, B. E. Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain. Archives of Oral Biology, v. 104, p. 33–39, 2019. DOI: https://doi.org/10.1016/j.archoralbio.2019.05.012.
WU, M. et al. Therapeutic agents for the treatment of temporomandibular joint disorders: progress and perspective. Frontiers in Pharmacology, v. 11, p. 596099, 2021. DOI: https://doi.org/10.3389/fphar.2020.596099.
ZWIRI, A. et al. Biomarkers for temporomandibular disorders: current status and future directions. Diagnostics, v. 10, n. 5, p. 303, 2020. DOI: https://doi.org/10.3390/diagnostics10050303.
ZUBRZYCKI, M. et al. Effects of centrally administered endocannabinoids and opioids on orofacial pain perception in rats. British Journal of Pharmacology, v. 174, n. 21, p. 3780–3789, 2017. DOI: https://doi.org/10.1111/bph.13906.
